ArticleHaematologica2023

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.

Ayalew Tefferi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.